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Abstract
Depression is associated with increased cardiovascular
mortality in patients with preexisting cardiac illness. A
decrease in cardiac vagal function as suggested by a
decrease in heart rate variability (HRV) or heart period
variability has been linked to sudden death in patients
with cardiac disease as well as in normal controls.
Recent studies have shown decreased vagal function in
cardiac patients with depression as well as in depressed
patients without cardiac illness. In this study, we com-
pared 20 h awake and sleep heart period nonlinear mea-
sures using quantification of nonlinearity and chaos in
two groups of patients with major depression and isch-
emic heart disease (mean age 59–60 years) before and
after 6 weeks of treatment with paroxetine or nortripty-
line. Patients received paroxetine, 20–30 mg/day or nor-
triptyline targeted to 190–570 nmol/l for 6 weeks. For
HRV analysis, 24 patients were included in the paroxe-
tine treatment study and 20 patients in the nortriptyline
study who had at least 20,000 s of awake data. The ages
of these groups were 60.4 B 10.5 years for paroxetine
and 60.8 B 13.4 years for nortriptyline. There was a sig-
nificant decrease in the largest Lyapunov exponent (LLE)
after treatment with nortriptyline but not paroxetine.
There were also significant decreases in nonlinearity
scores on SnetPR and SnetGS after nortriptyline, which may
be due to a decrease in cardiac vagal modulation of HRV.
SnetGS and awake LLE were the most significant variables
that contributed to the discrimination of postparoxetine
and postnortriptyline groups even with the inclusion of
time and frequency domain measures. These findings
suggest that nortriptyline decreases the measures of
chaos probably through its stronger vagolytic effects on
cardiac autonomic function compared with paroxetine,
which is in agreement with previous clinical and preclini-
cal reports. Nortriptyline was also associated with a sig-
nificant decrease in nonlinearity scores, which may be
due to anticholinergic and/or sympatholytic effects. As
depression is associated with a strong risk factor for car-
diovascular mortality, one should be careful about using
any drug that adversely affects cardiac vagal function.
Copyright © 2002 S. Karger AG, Basel
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Introduction
Major depression is associated with poor prognosis in
patients with heart disease [1–9]. Some studies have
shown decreased heart rate variability (HRV) in these
vulnerable patients with and without overt cardiac dis-
ease using linear and nonlinear techniques [10–13]. Roose
et al. [14, 15] have found that nortriptyline, a tricyclic
antidepressant, was associated with a higher rate of side
effects compared with paroxetine, a serotonergic reuptake
inhibitor in depressed patients with heart disease. Our
previous reports on time and frequency domain measures
of HRV in patients with anxiety after treatment with
imipramine, paroxetine and nortriptyline have shown
that nortriptyline as well as paroxetine were associated
with a significant decrease in high frequency (HF: 0.15–
0.5 Hz) HRV, though there was an increase in beat-to-
beat QT interval variability only in the nortriptyline
group, which suggests a relative increase in sympathetic
function and a decrease in cardiac vagal modulation after
treatment with nortriptyline [16–19]. The mean age group
of these patients was around 35 years and they did not
have a history of any heart disease.
An increase in cardiac sympathetic function or a
decrease in vagal function can lead to serious ventricular
arrhythmias and sudden death [20]. Recent noninvasive
techniques on HRV and QT variability show a great deal
of promise to study cardiac autonomic function in differ-
ent disorders and also to evaluate the effects of various
drugs [21–29].
Our findings on short-term and 24-hour HRV and
measures of nonlinearity and chaos suggest that patients
with depression and no heart disease have a significantly
decreased largest Lyapunov exponent (LLE) and also
decreased spectral power in different bands from 0 to
0.5 Hz of HR time series [12, 13]. This is important in
view of the strong association between decreased HRV
and significant cardiovascular mortality in patients with
cardiac disease, depression, anxiety, and also normal con-
trols [30–33]. Using frequency domain measures, HR
time series can usually be decomposed into very low fre-
quency (VLF: 0–0.04 Hz), low frequency (LF: 0.04–
0.15 Hz) and high frequency (HF: 0.15–0.5 Hz) bands
[34–36]. VLF power appears to be related to thermoregu-
lation and vascular mechanisms, LF power to sympathet-
ic as well as parasympathetic influences and HF power to
parasympathetic mechanisms.
Several investigators have pointed out and have dem-
onstrated the nonlinear nature of the HR or heart period
(HP) time series and have also shown the superiority or
the additional utility of these measures to the traditionally
used time and frequency domain measures [37–48]. Sev-
eral recent studies have stressed the importance of nonlin-
ear measures compared with the time and frequent do-
main measures of HR or HP. Poon and Merrill [49]
reported a decrease in cardiac chaos in severe congestive
heart failure, a condition associated with sudden death.
Voss et al. [50] showed that nonlinear measures seem to
be a better predictor of high arrhythmia risk than just the
global HRV, using multiparametric analysis. Makikallio
et al. [51] showed that fractal analysis of HR could be used
as a predictor of mortality in patients with depressed left
ventricular function after acute myocardial infarction.
Huikuri et al. [52] and Huikuri and Makikallio [53] dis-
cussed time and frequency domain, and nonlinear mea-
sures in their reports suggesting that the nonlinear mea-
sures of HRV are promising tools to stratify risk and as
predictors of death and life-threatening arrhythmia in
postinfarction populations. Thus, there is mounting evi-
dence to suggest that the nonlinear measures are clinically
very important.
Previous studies have suggested that tricyclic antide-
pressants result in tachycardia, prolongation of QTc inter-
val, decreased HRV and an increase in QT variability [19,
54, 58], which are all associated with significant cardio-
vascular events. Rechlin et al. [59] have shown that ami-
triptyline significantly decreases HRV in patients with
depression. On the other hand, Tucker et al. [60] have
reported that paroxetine increased cardiac vagal activity
in patients with panic disorder.
Thus, it is important to understand the effects of var-
ious antidepressant drugs on cardiac autonomic function
in various age groups of patients using these novel nonin-
vasive techniques. In this study, we sought to investigate
the effects of paroxetine and nortriptyline in patients with
major depression and ischemic heart disease aged about
60 years using HPV and Holter ECG records that were
obtained in a previous treatment study [61]. In the origi-
nal study, Roose et al. [61] have found that 61% of
patients on paroxetine and 55% on nortriptyline im-
proved after treatment. There was no significant change
in blood pressure or conduction intervals on ECG with
either drug. Paroxetine had no sustained effects on HR or
rhythm. However, nortriptyline produced a significant
increase in HR and a decrease in standard deviation (SD)
of all normal R-R intervals. Nortriptyline produced ad-
verse cardiac events in 18% of patients compared with
only 2% of patients in the paroxetine group. In our recent
study [62] on spectral measures and two nonlinear mea-
sures, fractal dimension and measures of symbolic dy-
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namics in the above group of patients, nortriptyline was
associated with significant vagolytic effects compared
with paroxetine. We also found that paroxetine increases
HR time series complexity as suggested by WC-100, one
of the measures of symbolic dynamics. In the present
study, we have specifically studied the measures of non-
linearity and chaos, which is quantified by obtaining the
LLE before and after treatment with paroxetine and nor-
triptyline. We hypothesized that nortriptyline treatment
would result in a significant decrease in the LLE in HR
time series.
Subjects and Methods
Subjects
Original Study Design. This study was conducted in four univer-
sity research centers [61], and was approved by the Internal Review
Boards at all 4 sites for the protection of subjects. The inclusion crite-
ria were the DSM-IV criteria for major depressive disorder, unipolar
subtype with a score of 16 or more on the 17-item Hamilton Rating
Scale for Depression (HAMD) [63], have ischemic heart disease and
be capable and willing to sign an informed consent to participate in
this study aimed at the cardiovascular safety of antidepressant medi-
cation. Patients were considered to have ischemic heart disease if
they had a myocardial infarction, coronary artery bypass graft sur-
gery, coronary angioplasty, a positive stress test, or angiographic evi-
dence of a 75% or greater luminal narrowing of a major coronary
artery or one of its primary branches. Patients were excluded if the
myocardial infarction occurred within 3 months prior to their
recruitment, with a baseline QTc of 460 ms or more, unstable or cres-
cendo angina and if they were receiving drugs with class I antiar-
rhythmic activity or warfarin.
After they had signed the informed consent, during a 2-week pla-
cebo period, baseline cardiac testing was conducted including a 24-
hour continuous Holter ECG record, as well as a routine 12-lead
ECG at the beginning and end of the placebo period. If the patients
had completed with the study procedures and continued to meet
inclusion and exclusion criteria at the end of the placebo period, they
were randomized by permuted blocks of 10 to treatment with either
paroxetine or nortriptyline for a double-blind 6-week trial.
Dosing. Patients less than 65 years of age received an initial dose
of paroxetine of 20 mg per day for the first 3 weeks, whereas older
patients were started at 10 mg per day for the first week and then the
dose was increased to 20 mg/day for the next 2 weeks. At the end of 3
weeks, if they did not show a 50% decrease in HAMD scores, paroxe-
tine was increased to 30 mg at week 4 and, if necessary, to 40 mg at
the end of week 5. The nortriptyline dose was begun at 25 mg, which
was increased to 50 mg by day 3. On the 7th day, the plasma level was
measured and the dose adjusted to achieve a plasma nortriptyline
level of 304 and 456 nmol/l. The idea was to have the dose within the
therapeutic range of 190–570 nmol/l (50–150 ng/ml). Medication
compliance was monitored by weekly pill counts in addition to plas-
ma level measurements in blood samples that were also taken from
patients on paroxetine.
Drug Discontinuation. Drug discontinuation was done due to an
adverse cardiac event, if there was a greater than 50% increase in the
QRS interval from baseline, QRS interval exceeded 180 ms in
patients with a bundle-branch block at baseline, the QTc interval
exceeded 500 ms and if the patient developed a proarrhythmic effect.
Additional things that were taken into account were significant blood
pressure changes, cardiac enzyme levels and 24-hour ECG.
Cardiac Assessment. As stated above, 24-hour ECG was obtained
before and after 2 weeks of placebo administration. Patients received
active medication for 6 weeks. Twenty-four-hour ECGs were then
repeated at the end of 2 and 6 weeks of medication treatment. Thus,
complete data included four 24-hour ECG records.
The mean B SD for paroxetine dose was 22 B 5 mg/day, and 74
B 30 mg/day for nortriptyline. At week 6, the nortriptyline levels
were within the therapeutic range. In the original sample, 37/41
(90%) of patients treated with paroxetine completed the trial and 25
(68%) were responders. Sixty-five percent (26/40) completed the nor-
triptyline trial and 22 (85%) were responders.
Present Study on Measures of HRV
This study included only those patients who had at least 20,000 s
of data during the awake period and who had a pretreatment record,
which was a preplacebo record, and a second one 6 weeks after treat-
ment. Many patients did not have all four and that is the reason why
we had to limit our analyses to two records only. However, we com-
pared pre- and postplacebo lead-in records and found no significant
difference in any of our HRV measures. One other reason to exclude
the 2-week posttreatment record was that the effects of the drugs
might not have been observable by then. Twenty-four patients were
included in the paroxetine treatment study and 20 patients in the
nortriptyline study. We have used means and SD throughout the text
and tables of this paper. Thirty-three patients had 20-hour data, 44
had awake data and 30 sleep data.
Twenty-four-hour ECG was recorded using cassette tapes, was
digitized by a Marquette 8,000 scanner, and QRS labeling and edit-
ing was done using standard Marquette algorithms. Then, the ASCII
files of R-R intervals in milliseconds were edited according to pre-
vious techniques described in detail [64–67]. These data were edited
using software which eliminated any premature ventricular beats.
This method was similar to the one used by Huikuri et al. [64]. An
R-R interval was interpreted as a premature beat if it deviated from a
previous qualified interval by more than a tolerance level of 30%.
These data were eliminated and the resulting gaps were filled with an
average value in the immediate neighborhood. The edited time series
were then sampled at 2 Hz using the technique described by Berger et
al. [68], to obtain the instantaneous HR. This stepwise continuous
instantaneous HR signal maintains an amplitude equal to the recip-
rocal of the R-R interval and the convolution of the HR signal with
the rectangular window has the effect on the power spectrum of mul-
tiplication by a low-pass filter. A 2-Hz sampling rate would allow an
accurate estimation of the power spectrum up to 0.5 Hz, which is
equivalent to a breathing rate of 30/min. From here on, all the data
were converted to R-R interval time series [60,000/HR in beats per
minute (bpm)]. Then, the data were detrended using a linear detrend-
ing technique prior to the other analyses except for the nonlinear
analyses.
Spectral Analysis
The power spectrum was obtained as the magnitude squared of
the Fourier transform using a rectangular data window. The powers
were integrated in the following bands: total power (TP, 0–0.5 Hz),
ultra-low frequency power (ULF, 0–0.0033 Hz), VLF (0.0033–
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0.04 Hz), LF (0.04–0.15 Hz) and HF (0.15–0.5 Hz). For spectral
analysis, we used 20-hour data, and awake and sleep data of 20,000 s
of duration. These data had been presented in our previous report
[62]. We used awake and sleep spectral powers in ULF, VLF, LF and
HF bands for entering into discriminant function analysis and multi-
ple regression analysis in addition to the nonlinear measures to com-
pare the paroxetine and nortriptyline groups after treatment.
Nonlinear Analyses
The methods have been described in great detail in our previous
reports [13, 44–46], and are described here again in some detail. The
reconstruction of HR time series and the calculation of the minimum
embedding dimension (MED), the LLE and nonlinearity scores were
all computed using a PC with custom-designed software according to
the following methods.
Time Delay Embedding and Attractor Reconstruction
The first step in nonlinear dynamical analysis is the reconstruc-
tion of an attractor in phase-space; since we do not know a priori the
coordinates of the phase-space, it is necessary to derive them from
observed time series.
Estimation of MED
The proper reconstruction of an attractor is guaranteed if the
dimension of phase-space is sufficient to unfold the attractor. It is
shown that an embedding dimension of m 6 2d + 1 can achieve this,
where d is the dimension of the attractor [69]. In most cases of
observed time series analysis, we neither have knowledge of d nor of
m. There are many different algorithms used in the estimation of
these quantities [70–74], but many of them have the disadvantage of
either being too subjective, requiring a large number of data points or
being computationally very intensive. The method proposed by Cao
[75] overcomes these difficulties and is suitable for short-term time
series. Additionally, this method gives more reliable estimates of
MED, even when the dimension is sufficiently large.
Another quantity is determined which is useful in distinguishing
deterministic signals from stochastic signals and it is given by
E* (m ) = 
1
N – mÙ
N – mÙ
™
t = 1
A x i + mÙ – xn (i, m ) + mÙ A (1)
and its variation from m to m + 1 as
E2(m ) = E* (m + 1)/E* (m ) (2)
where n (i, m ) has the same meaning defined earlier (equation 1). For
random time series, E1(m ) will never attain a saturation value as m
is increased, but because of limited data samples and practical com-
putations, it may be difficult to ascertain whether E1(m ) is slowly
changing or has stopped changing. In such a situation, E2(m ) will be
very useful, since for random data, future values are independent of
past values. E2(m ) will be equal to 1 for any m, whereas for deter-
ministic signals, there exist some values of m such that E2(m ) 1. We
computed both E1(m ) and E2(m ).
This method was applied on time series of some of the standard
maps and we found their MED tallying with the literature.
Subjectivity of Arriving at MED
Though it is a cause for some concern when the MEDs are calcu-
lated by many people, this can be substantially reduced by training
only a few people to do so, and in this particular paper, one of the
authors who was blind to the patients’ condition has calculated all the
MED. We chose the point of the beginning of saturation on the graph
after plotting the E1 values.
Largest Lyapunov Exponent
We used the method of Rosenstein et al. [76] to calculate the LLE.
Lyapunov exponents (LEs) are another invariant, which could be
used to characterize the dynamical system. It quantifies sensitivity of
the system to initial conditions. An m-dimensional dynamical sys-
tem has m LEs. The presence of a positive LE indicates chaos. It also
quantifies the amount of instability or predictability of the system. A
fully deterministic system will have a zero LE since it is fully predict-
able, whereas a random system will have a large positive exponent
indicating no predictability. In most applications, it is sufficient to
compute only the LLE instead of all LEs. There are many algorithms
available to estimate the LLE and the Lyapunov spectrum [77–80].
Most of them are unreliable when operated on small data sets. In our
present work, we used the method proposed by Rosenstein et al. [76]
which is robust against small data length [76].
In practice, the LE is easily and accurately estimated using a least-
square fit to the ‘average’ line defined by
Á (n ) = 
1
¢t
lndi (n ) (3)
where   denotes the average over all values of i. This last averaging
step is the main feature that allows an accurate evaluation of Ï even
when we have a short and noisy data set.
Tests for Nonlinearity
The erratic fluctuations that are observed in an experimental
time series owe their dynamical variation to a mix of various
influences: chaos, nonchaotic but still nonlinear determinism, linear
correlation and noise, both in the dynamics and in the measuring
setup. This emphasizes the need for estimating the nonlinear struc-
ture in the time series. In our present work, we investigated the non-
linear structure present with HRV time series using two methods,
and we checked whether nonlinear time correlations were present
among the time series values. Both methods are based on the analysis
of the extrema (local maxima or minima) as proposed by Di Garbo et
al. [81].
Nonlinearity Test Based on Extrema of a Time Series
It has been shown that the dynamical behavior of the real time
solution of an ordinary differential equation is strongly connected to
its analytic properties in the complex time plane, and in particular to
the distribution of the singularities nearest to the real axis [82]. The
second consideration arises from a general property of a stochastic
process, which states that given a mean square differentiable stochas-
tic process, x (t ), the expected number of its extrema for unit time is
contained in the joint density function of x (t ), x. (t ) and x.. (t ) [83].
These theoretical and numerical results suggest that the sequence of
extrema of a time series contains dynamical information of the pro-
cess generating them. Both methods statistically discriminate mea-
sures which are evaluated based on extremas for original and surro-
gate data sets.
Two types of surrogates are considered in our analysis, Fourier
shuffled (GS) and phase randomized (PR) surrogates.
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Table 1. Nonlinear measures of HP before and after treatment
Paroxetine
predrug postdrug
Nortriptyline
predrug postdrug
20 h
R-R mean 839.04B122.82 868.89B126.70 825.53B152.34 736.24B133.06*
R-R SD 111.44B41.04 111.47B36.11 112.50B65.68 101.24B43.47
SpscGS 1.76B0.48 2.03B0.40 1.90B0.50 1.95B0.39
SpscPR 3.13B1.40 4.18B2.69 3.05B1.11 3.22B1.38
SnetGS 5.52B2.02 6.47B1.62 6.19B1.96 4.64B1.44***
SnetPR 4.93B2.13 6.41B1.72 5.61B2.29 4.16B1.81***
MED 13.11B1.26 12.76B1.36 12.95B1.78 13.55B0.88
LLE 0.10B0.01 0.11B0.02 0.11B0.11 0.09B0.013*
Awake
R-R mean 788.85B123.92 836.37B110.26 823.61B148.47 719.31B123.20*
R-R SD 86.91B40.75 87.40B25.49 96.21B50.77 65.70B26.71*
SpscGS 1.83B0.61 2.26B0.66 2.14B0.61 2.19B0.74
SpscPR 3.59B2.66 3.64B2.87 3.66B3.41 4.07B2.23
SnetGS 5.42B2.27 5.95B1.6 5.99B2.40 4.2B1.9***
SnetPR 4.93B2.42 5.6B2.0 6.08B3.89 3.6B2.1***
MED 13.30B1.58 12.45B1.31 13.08B1.75 13.16B1.22
LLE 0.11B0.02 0.11B0.01 0.11B0.01 0.10B0.01**
Sleep
R-R mean 931.85B124.98 999.47B139.52 931.32B246.03 857.40B140.98
R-R SD 87.36B26.84 82.49B20.63 90.66B41.37 75.07B35.49
SpscGS 1.81B0.71 1.83B0.58 1.66B0.60 1.74B0.35
SpscPR 2.92B1.31 4.40B4.59 2.69B0.95 2.90B2.84
SnetGS 5.75B1.90 7.1B1.9 6.36B1.84 5.2B2.2***
SnetPR 5.13B2.15 6.7B2.1 5.60B2.05 4.6B2.5**
MED 13.08B1.35 12.90B1.64 12.80B1.98 13.59B1.11
LLE 0.10B0.01 0.11B0.02 0.11B0.02 0.09B0.01*
* p ! 0.025; ** p ! 0.01; *** p ! 0.005. Significant difference between the posttreatment values of the paroxetine
and nortriptyline groups (Student’s t test, two-tailed). R-R mean and SD are milliseconds.
Pattern of Singularities in the Complex Time Plane Algorithm
The steps involved in quantifying nonlinear correlations with the
pattern of singularities in the complex time plane (PSC) method are:
(1) determine the couples {stj, tj for j  = 1, 2, ..., n } corresponding to
local maxima and time at which it occurred;
(2) determine the length of the broken line joining these extremas,
L = 
n – 1
™
j = 1
{(Stj + 1 – stj )2 + (tj + 1 – tj )2} (4)
(3) n number of surrogates are generated and L for each surrogate is
computed;
(4) determine mean L and SD Ûs of these quantities;
(5) determine the measure of significance as proposed by Theiler et
al. [84],
Spsc = 
AL – Ls A
Ûs
(5)
Number of Extrema for Unit Time
The protocol of the number of extrema for unit time (NET) meth-
od involves the following steps:
(1) the number of extrema No for unit time, To of the given time series
is determined and used as discriminating statistics;
(2) n numbers of surrogate data sets are generated and the number of
extremas for each surrogate set Ni (i  = 1,... n ) are computed;
(3) the average NET Ns and their SD Ûs are determined and they are
statistically discriminated by computing the significance
Snet = 
ANo – Ns A
Ûs
(6)
Again, two types of surrogates are considered in our analysis, i.e. GS
and PR surrogates. These are referred to as SnetGS and SnetPR, respec-
tively.
The reason to publish this as a separate report from our recent
study on frequency domain measures [62] is that we obtained
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256-second HR time series data every 2 h for 24 h (12 segments) and
used only those subjects who had at least 6 such segments for the day.
Even when we strictly limited the data to four 256-second segments
to truly reflect awake and sleep periods, we obtained very similar
results. Then, we used the mean of these 12 5-min segments, the
mean of the first 6 segments, which mainyl reflected daytime, and the
mean of the last 6 segments, which mainly reflected nighttime. We
used each of these 256 s for the estimation of the LLE and all the
above nonlinear measures. Due to the amount of time involved in the
computation of these analyses for 4 nonlinear scores and the LLE
(300 24-hour records ! 72 analyses), we limited it to 256-second
segments. For longer data lengths, MED and LLE take up an enor-
mous amount of computing time.
Statistical Analysis
First, we used a three-way ANOVA with paroxetine and nortrip-
tyline as the grouping variables, sleep and awake as one within factor
and pre- and posttreatment as the second repeated measure. Signifi-
cant main or interaction effects were followed up with two-way
ANOVA for repeated measures with the drug condition as the group-
ing factor and pre- and posttreatment (6 weeks) measures as the
repeated measures for the mean of 12 epochs, and also day and night
epochs (mean of 6 segments of 5 min each). The day and night epochs
were obtained in two different ways. First, we used the average of the
first 6 and the last 6 segments and, in addition, we also divided them
into the mean of the first 4 (awake) segments and the mean of the 7th
to 10th segment, which significantly reflected sleep. Significant
effects were followed up by paired t tests to compare patients sepa-
rately for each drug condition. All tests were two-tailed and a proba-
bility value of 0.025 was accepted as significant as we performed two
post hoc t tests. Pearson’s product-moment correlations were used to
examine the relationship between HPV measures of interest and
treatment effects. For those subjects who had data before and after
placebo lead-in, the HPV measures were compared using ANOVAs
for repeated measures. Pearson product-moment correlations were
performed to examine the relationship between nonlinear measures
and improvement in depression scores (HAMD) after treatment for
either drug condition separately. As several correlations were per-
formed, the significance level was set at p ! 0.025.
We used only awake and sleep spectral powers in ULF, VLF, LF
and HF bands for entering into step-wise regression analysis and dis-
criminant function analysis along with the nonlinear measures to
compare paroxetine and nortriptyline groups after treatment.
Results
Age was very similar between the paroxetine and nor-
triptyline groups. There were no significant group differ-
ences between baseline and after placebo lead-in periods
for any of the HP variables. In fact, some of the values
were almost identical. There was no gender effect for any
of the analyses. For the awake and sleep periods, using the
mean of 6 or 4 epochs has not made any significant
changes in the results of ANOVA and t tests. Tables 1–3
show the results of three- and two-way ANOVAs along
with results of t tests in table 1.
Table 2. Results of three-way ANOVA comparing the two drug con-
ditions as the grouping factor and pre- and posttreatment and awake
and sleep periods as repeated measures
F d.f. p
SpscGS
S 15.69 1, 33 0.0004
Sx 4.98 1, 33 0.0326
SnetGS
Tx 7.38 1, 33 0.0104
S 15.55 1, 33 0.0004
SnetPR
Tx 9.51 1, 33 0.0041
S 11.93 1, 33 0.0015
LLE
TS 4.66 1, 23 0.04
x = Group effect; S = awake vs. sleep effect; T = treatment (pre-
vs. posteffect).
Table 3. Results of two-way ANOVA comparing the two drug condi-
tions as the grouping factor and pre- and posttreatment awake and
sleep periods separately
Group
effect
Treatment
effect
Interaction effect
Awake
SpscPR NS NS NS
SpscGS NS NS NS
SnetPR NS NS F = 6.9; d.f. = 1, 40;
p = 0.01
SnetGS NS NS F = 4.1; d.f. = 1, 40;
p = 0.05
MED NS NS NS
LLE NS NS F = 4.1; d.f. = 1, 23;
p = 0.05
Sleep
SpscPR NS NS NS
SpscGS NS NS NS
SnetPR NS NS F = 5.6; d.f. = 1, 33;
p = 0.02
SnetGS NS NS F = 8.93; d.f. = 1, 33;
p = 0.005
MED NS NS NS
LLE NS F = 9.7;
d.f. = 1, 28;
p = 0.004
NS
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Table 1 shows the mean B SD of all HP variables with
the significant differences between paroxetine and nor-
triptyline groups before and after treatment. We have
chosen to do this for two reasons. Firstly, repeated-mea-
sures ANOVA has only shown significant decreases in
SnetGS and SnetPR, and LLE for the nortriptyline condition.
As there were fewer subjects for this comparison and as
there were no significant differences between baseline
(pre-) paroxetine and nortriptyline values for the above
measures, we chose to present the results of the t tests
between post-paroxetine and post-nortriptyline values as
there were more subjects in each group.
There were significant decreases in SnetGS and SnetPR,
and LLE after nortriptyline treatment. The decrease in
mean R-R interval and SD of R-R intervals was signifi-
cant after nortriptyline, as expected.
Discriminant Function Analysis
When only spectral powers of HP after treatment were
used, total and VLF power contributed significantly to the
discrimination between the two treatments (p ! 0.05).
However, when all nonlinear and spectral variables are
entered, only 12-epoch SnetGS and 6-epoch average awake
LLE were the significant discriminators. Stepwise multi-
ple regression analysis confirmed these findings (table 4).
Correlations
At baseline, before treatment, there were no significant
correlations between nonlinear measures and HAMD.
For the postparoxetine treatment condition, there were no
significant correlations between nonlinear measures and
the final HAMD score. There was a significant positive
correlation between sleep LLE and HAMD (r = 0.54; p !
0.02) for post-nortriptyline condition.
Discussion
Decreased LLE and Nonlinear Scores after
Nortriptyline
The decrease in the LLE after nortriptyline is an
important finding in this study as the LLE is a measure
that is related to predictability, and a positive value usual-
ly indicates a degree of chaos. As described in the intro-
duction, some of the nonlinear measures including the
LLE are decreased in cardiac patients with poor progno-
sis. Thus, in a population that is already vulnerable, such
as patients with ischemic heart disease and depression,
the use of drugs like nortriptyline appears undesirable. As
the evidence cited in the introduction also links the LLE
to overall cardiac vagal function, any decrease in the LLE
may be detrimental in vulnerable populations. On the
other hand, paroxetine had no such effects. Similarly,
there was a significant decrease in SnetGS and SnetPR only
after nortriptyline. Nonlinearity measures basically pro-
vide information as to the deviation of the time series
from linear surrogates. The interrelation or interaction of
certain constants from Lorenz equations reveals the
amount of linearity or nonlinearity in the system dynam-
ics and this can be quantified as described above. Thus,
the decrease in the interaction of some of these constants
may have contributed to decreased nonlinearity scores,
which most likely is due to the anticholinergic effect of
nortriptyline. This is also in line with a much less signifi-
cant antimuscarinic effect of paroxetine.
Previous Frequency Domain Analyses and Measures
of Symbolic Dynamics on this Data Set
These analyses clearly showed a significantly more
vagolytic effect for nortriptyline. However, it was interest-
ing to note that paroxetine increased WC-100, a measure
of symbolic dynamics, which indicates nonlinear com-
plexity. Thus, the present findings are mostly in agree-
ment with our previous report [62].
Table 4. Results of stepwise regression
analysis for the variables that significantly
discriminated paroxetine and nortriptyline
groups at the end of treatment
Multiple r R2 Change p
SnetGS (12-epoch mean) 0.76 0.58 0.58 !0.01
Awake LLE (6-epoch mean) 0.83 0.70 0.11 !0.05
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Multiple Discriminant Function Analysis and Stepwise
Regression Analysis
As described above, nonlinear measures were the most
significant in discriminating posttreatment paroxetine
and nortriptyline patients. This may be clinically very
important because it is the nortriptyline group that had
decreased variability and complexity of HP time series,
which certainly is a risk factor for significant cardiovascu-
lar events.
Paroxetine and Antimuscarinic Effects
Compared with tricyclics, paroxetine has a weak affini-
ty for muscarinic receptors, 15-fold weaker than amitrip-
tyline [85, 86]. Fluoxetine and paroxetine did not produce
any significant change in this variable. Pollock et al. [87]
also reported that at therapeutic plasma concentrations,
paroxetine is associated with approximately 1/5th of the
anticholinergic effect of nortriptyline in older patients.
The study by Owens et al. [88] also suggests that paroxe-
tine does not have significant affinity for muscarinic
receptors. Thus, all the above studies support a lack of
significant antimuscarinic effects for paroxetine in this
study group.
Cardiac Autonomic Function, Nonlinear Measures
and Cardiovascular Mortality
Cole et al. [89] have recently shown that exercise recov-
ery time is prolonged in people who are prone to have
significant cardiovascular events which again relates im-
paired cardiac vagal function to a significant risk for car-
diovascular mortality. Several studies have shown a de-
creased LLE probably related to decreased central vagal
function, which may be related to significant cardiovascu-
lar events in patients with various neurological conditions
[90–94]. It has also been well documented that a relative
increase in cardiac sympathovagal balance can lead to
serious ventricular arrhythmia [95, 96]. Thus, any nonin-
vasive measure that reflects cardiac vagal function is a
valuable tool to study sudden cardiac death and poor
prognosis in cardiac patients. Carney et al. [97] have
shown an improvement in the parameters of HRV in
depressed patients with myocardial infarction who under-
went cognitive psychotherapy. Thus, the effectiveness of
various treatment approaches should be evaluated in the
context of cardiovascular effects and probably some of
these new nonlinear measures may be of additional value.
Some other measures, including measures of chaos, may
prove very effective to identify other subtle changes in
autonomic function.
Correlation of HAMD with Posttreatment
Nonlinearity Measures and LLE
It is interesting to note that the final HAMD (a lower
score indicates better improvement) significantly corre-
lated with the LLE, indicating that a decreased cardiac
vagal function may be associated with a lower HAMD
score, which again may indicate a stronger effect of nor-
triptyline in regard to its antimuscarinic effects in these
patients. This may not suggest that the antimuscarinic
effect itself is responsible for the treatment effect, but the
overall antidepressant effect of the drug might be associat-
ed with a strong anticholinergic activity.
Conclusions
The findings of this study suggest a significant decrease
in chaos of HP time series, probably due to the vagolytic
effect of nortriptyline in patients with major depression
and cardiac disease and thus between the two drugs;
paroxetine may be a safer choice especially in the patients
with myocardial infarction. This may be likely due to the
weaker antimuscarinic effects of paroxetine.
Limitations
We had to exclude people in the placebo group (after
placebo lead-in), as this was leaving us with fewer subjects
for comparison. However, as mentioned, the values of
various linear and nonlinear HRV measures were very
similar and there were no significant differences between
these two pre- and postplacebo periods. The measures of
nonlinearity scores and LLE are relatively new and future
prospective studies should validate their additional utility
to the more traditional time and frequency domain mea-
sures.
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